Sulfadiazine is an antibiotic.[1] Used together with pyrimethamine, a dihydrofolate reductase inhibitor, it is the treatment of choice for toxoplasmosis, which is caused by a protozoan parasite.[3] It is a second-line treatment for otitis media, prophylaxis of rheumatic fever, chancroid, chlamydia, and infections by Haemophilus influenzae.[1] It is also used as adjunct therapy for chloroquine-resistant malaria and several forms of bacterial meningitis.[4] It is taken by mouth.[1] Sulfadiazine is available in multiple generic tablets of 500 mg. For urinary tract infections, the usual dose is 4 to 6 grams daily in 3 to 6 divided doses.[4]
 | |
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682130 |
| Routes of administration | Topical cream, by mouth |
| Drug class | Antibiotic (sulfonamide)[1] |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 38-48%[1] |
| Metabolism | Liver (acetylation)[1] |
| Elimination half-life | 7-17 hours [1] |
| Excretion | Urine [1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.000.623 |
| Chemical and physical data | |
| Formula | C10H10N4O2S |
| Molar mass | 250.28 g·mol−1 |
| Melting point | 252 to 256 °C (486 to 493 °F) |
  (what is this?) (verify) | |
Common side effects include nausea, diarrhea, headache, fever, rash, depression, and pancreatitis.[1] It should not be used in people who have severe liver problems, kidney problems, or porphyria.[3] If used during pregnancy, it may increase the risk of kernicterus in the baby.[1] While the company that makes it does not recommend use during breastfeeding, use is believed to be safe if the baby is otherwise healthy.[2] It is in the sulfonamide class of medications.[1]
Sulfadiazine was approved for medical use in the United States in 1941.[1][5] It is on the World Health Organization's List of Essential Medicines.[6] Sulfadiazine is available as a generic medication.[1]
Medical uses
editIt eliminates bacteria that cause infections by stopping the production of folate inside the bacterial cell, and is commonly used to treat urinary tract infections and burns.
In combination, sulfadiazine and pyrimethamine can be used to treat toxoplasmosis, the disease caused by Toxoplasma gondii.
Other uses
editSulfadiazine is used in plant research for selecting and maintaining genetically manipulated cells.[7]
Mechanism of action
editSulfadiazine works by inhibiting the enzyme dihydropteroate synthetase.
Side effects
editSide effects reported for sulfadiazine include nausea, loss of appetite, dizziness, gastrointestinal upset, rash and fever.[4]
Brand names
editThis drug is sold branded as Lantrisul, Neotrizine, Sulfa-Triple #2, Sulfadiazine, Sulfaloid, Sulfonamides Duplex, Sulfose, Terfonyl, Triple Sulfa, Triple Sulfas, and Triple Sulfoid.
See also
editReferences
edit- ^ a b c d e f g h i j k l m "Sulfadiazine". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.
- ^ a b "Sulfadiazine Use During Pregnancy | Drugs.com". www.drugs.com. Archived from the original on 20 December 2016. Retrieved 28 June 2017.
- ^ a b World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. pp. 126, 205. hdl:10665/44053. ISBN 9789241547659.
- ^ a b c "Sulfadiazine", LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012, PMID 31643992, retrieved 2021-12-27
- ^ "Drugs@FDA: FDA Approved Drug Products". www.accessdata.fda.gov. Retrieved 11 November 2018.
- ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ Kobercová E, Srba M, Fischer L (March 2023). "Sulfadiazine and phosphinothricin selection systems optimised for the transformation of tobacco BY-2 cells". Plant Cell Reports. 42 (3). Springer Science and Business Media LLC: 535–548. doi:10.1007/s00299-022-02975-7. PMID 36609768. S2CID 255501050.
External links
edit- "Sulfadiazine". Drug Information Portal. U.S. National Library of Medicine.
